72331-40-9

Usage

Uses

Used in Pharmaceutical Industry:
1,3,4,7-Tetrahydro-2H-1,3-diazepin-2-one serves as a crucial intermediate in the synthesis of various pharmaceutical compounds. Its unique ring structure allows for the development of new drugs with potential applications in treating a range of medical conditions.
Used in Agrochemical Industry:
1,3,4,7-Tetrahydro-2H-1,3-diazepin-2-one also plays a significant role in the agrochemical sector, where it is utilized as an intermediate in the production of agrochemicals. Its incorporation can lead to the development of more effective pesticides and other agricultural products.
Used in Heterocyclic Compounds Production:
1,3,4,7-Tetrahydro-2H-1,3-diazepin-2-one acts as a building block for the creation of diverse heterocyclic compounds. These compounds are essential in various chemical and pharmaceutical applications due to their unique properties and reactivity.
Used in Scientific Research:
1,3,4,7-Tetrahydro-2H-1,3-diazepin-2-one has been studied for its potential pharmacological properties, particularly its effects on the central nervous system. This research opens up possibilities for discovering new therapeutic agents and deepening our understanding of neurological processes.
Overall, 1,3,4,7-Tetrahydro-2H-1,3-diazepin-2-one is a valuable chemical with applications spanning the pharmaceutical, agrochemical, and scientific research industries, as well as in the synthesis of heterocyclic compounds.

Upstream product

• 463-58-1 carbon oxide sulfide 
• 40794-72-7 cis-1,4-diamino-2-butene 
• 1413176-86-9 tert-butyl 3-(4-methoxybenzyl)-2-oxo-2,3,4,7-tetrahydro-1H-1,3-diazepine-1-carboxylate 
• 40794-71-6 cis-1,4-diphthalimido-but-2-ene 

Downstream Products

• 19055-93-7 1,3-diazepan-2-one 
• 1251462-76-6 1-(3,3-difluoro-4-benzoyloxy-5-benzoyloxymethyl-tetrahydro-furan-2-yl)-1,3,4,7-tetrahydro-[1,3]diazepin-2-one 
• 1251462-79-9 1-(3,3-difluoro-4-benzoyloxy-5-benzoyloxymethyl-tetrahydro-furan-2-yl)-1,3,4,7-tetrahydro-[1,3]diazepin-2-one 
• 75421-14-6 C₃₁H₂₈N₂O₉ 
• 75421-15-7 C₃₁H₂₈N₂O₉ 
• 75421-16-8 C₃₁H₂₈N₂O₉ 
• 75421-17-9 C₃₁H₂₈N₂O₉ 
• 75421-13-5 C₃₇H₃₄N₂O₉Se 
• 75421-12-4 C₃₇H₃₄N₂O₉Se 
• 75421-10-2 (2R,3R,4R,5R)-2-(benzoyloxymethyl)-5-(2-oxo-2,3,4,7-tetrahydro-1H-1,3-diazepin-1-yl)tetrahydrofuran-3,4-diyl dibenzoate 
• 75421-11-3 1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3,4-dihydro-1H-1,3-diazepin-2(7H)-one 
• 183861-30-5 4-Methyl-benzoic acid 2-hydroxy-5-(2-oxo-2,3,4,7-tetrahydro-[1,3]diazepin-1-yl)-5-(2,2,2-trifluoro-acetylamino)-pentyl ester 
• 75421-08-8 (5S,6S)-5-Hydroxy-6-phenylselanyl-[1,3]diazepan-2-one 

Relevant academic research and scientific papers

A facile synthetic route to diazepinone derivatives via ring closing metathesis and its application for human cytidine deaminase inhibitors

A variety of diazepinone derivatives were prepared from α-amino acids and amino alcohols by a new synthetic methodology based on ring closing metathesis as a key step. The diazepinones were coupled with ribose derivatives to afford novel diazepinone nucleosides. Among them, (4R)-1-ribosyl-4-methyl-3, 4-dihydro-1H-1,3-diazepin-2(7H)-one (3) showed a potent inhibitory effect (Ki = 145.97 ± 4.87 nM) against human cytidine deaminase.

(2 ' -DEOXY-RIBOFURANOSYL) -1,3,4, 7-TETRAHYDRO- (1,3) IAZEPIN-2-0NE DERIVATIVES FOR TREATING CANCER

Provided herein are compounds used to inhibit the deamination enzyme responsible for the inactivation of therapeutic compounds, and methods of using them.

Cyclic Urea Nucleosides. Cytidine Deaminase Activity as a Function of Aglycon Ring Size

Five β-D-ribofuranosyl cyclic urea nucleosides (14-18), ranging in size from five to eight membered, were synthesized and evaluated as cytidine deaminase (CDA) inhibitors.The precursor protected nucleosides (9-13) were prepared by a condensation procedure

Seven-membered ring compounds as inhibitors of cytidine deaminase

Seven-membered heterocyclic nucleosides used to inhibit the deamination enzyme responsible for the inactivation of arabinosylcytosine (ara--C). Preferred nucleosides containing a seven-member aglycone are as follows: STR1 Preferred aglycones are as follow

1,3-Diazepinones. 1. Synthesis of 5-Hydroxyperhydro-1,3-diazepin-2-one

The synthesis of 5-hydroxyperhydro-1,3-diazepin-2-one (3) is accomplished by two different routes.The first route involves the reduction of the precursor ketone 2, which is synthesized in seven steps from levulinic acid (5).The second approach makes use of the hydration of the symmetrically unsaturated precursor 4 via the hydroboration-oxidation procedure.This precursor in turn is obtained by direct cyclization of cis-1,4-diamino-2-butene (12).